In Ph-B-ALL patients, 53/126 (42.1%) cases carried CDKN2A/B deletion; the survival of these patients was inferior to those without CDKN2A/B deletion (N=73). This evidence concerns the gene CDKN2A and acute lymphoblastic leukemia.